Linguistic-cognitive intervention in a case of early-onset Alzheimer's disease.
Naming scores stayed stable over 12 months of weekly speech therapy in a 58-year-old woman with early-onset Alzheimer's, while her overall cognitive score fell from 53 to 30.
She reported feeling less afraid to speak. One person, not a pattern.
Key findings
1Over 12 months of follow-up, the patient's overall cognitive score (ACE-R) fell from 53 to 30 across four evaluations. The Memory subtest showed a statistically significant decline (p = 0.024), and the total ACE-R score also reached significance (p = 0.052).
2Naming performance on the Boston Naming Test remained relatively stable across the four evaluations (39, 33, 40, 33 correct answers without a clue; p = 0.624). The only statistically significant language decline was in the ABCD Reading comprehension subtest (p = 0.019).
3When asked about changes after starting speech therapy, the patient said: 'Before I was afraid to speak because I was stuck, now, even with difficulties, I do not stop expressing myself.'
Still to come
How it was doneWhat they foundWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
One patient. Nothing in this case can be generalised to other people with early-onset AD or to any other dementia diagnosis. The anticholinesterase drug (Rivastigmine) was stopped by the patient's husband in May 2024, roughly four months before the intervention ended, so the final phase of therapy was conducted without it. The authors list this as a limitation. Sessions were interrupted during school holidays at the university where treatment was delivered. The patient held a doctorate, which the authors identify as a source of cognitive reserve that may have protected her language scores independently of the therapy. There is no control condition and no way to separate the effect of the speech-language intervention from the natural course of the disease or from the patient's cognitive reserve. The authors themselves note the scarcity of studies on speech-language intervention for early-onset AD and frame this case as a contribution to building evidence in that area.
Declared interests
The authors declared no financial support and no conflicts of interest.
The easy way to misread this
Do not read the stable naming scores as proof that this speech-language programme works for early-onset Alzheimer's. This is one woman with a doctorate, her anticholinesterase was stopped in May 2024, and there is no way to separate the therapy effect from her cognitive reserve or the natural course of the disease. The significant cognitive decline (ACE-R total p = 0.052, Memory p = 0.024) is the expected trajectory of a neurodegenerative condition, not a treatment failure.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →